Zacks Investment Research Lowers Supernus Pharmaceuticals (SUPN) to Hold

Supernus Pharmaceuticals (NASDAQ:SUPN) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Friday, January 12th.

According to Zacks, “Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland. “

Several other research firms have also recently weighed in on SUPN. Stifel Nicolaus cut Supernus Pharmaceuticals from a “buy” rating to a “hold” rating and set a $47.00 price target for the company. in a report on Tuesday, September 19th. They noted that the move was a valuation call. Cantor Fitzgerald reissued a “buy” rating and set a $49.00 price target on shares of Supernus Pharmaceuticals in a report on Tuesday, September 19th. BidaskClub raised Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Thursday, January 11th. SunTrust Banks reissued a “buy” rating and set a $61.00 price target on shares of Supernus Pharmaceuticals in a report on Friday, November 3rd. Finally, Cowen set a $50.00 price target on Supernus Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, October 23rd. Three equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. Supernus Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $49.90.

Supernus Pharmaceuticals (NASDAQ:SUPN) traded up $3.35 on Friday, hitting $46.90. The stock had a trading volume of 1,233,700 shares, compared to its average volume of 747,031. Supernus Pharmaceuticals has a 52 week low of $23.10 and a 52 week high of $50.04. The firm has a market capitalization of $2,440.00, a PE ratio of 42.64 and a beta of 1.17.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its quarterly earnings data on Monday, November 6th. The specialty pharmaceutical company reported $0.29 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.27 by $0.02. The company had revenue of $80.40 million during the quarter, compared to analysts’ expectations of $78.74 million. Supernus Pharmaceuticals had a return on equity of 26.37% and a net margin of 20.98%. Supernus Pharmaceuticals’s revenue was up 41.5% on a year-over-year basis. equities analysts forecast that Supernus Pharmaceuticals will post 1.07 earnings per share for the current year.

In other Supernus Pharmaceuticals news, VP Victor Vaughn sold 15,000 shares of the firm’s stock in a transaction on Tuesday, January 9th. The stock was sold at an average price of $42.04, for a total transaction of $630,600.00. Following the transaction, the vice president now owns 24,344 shares in the company, valued at approximately $1,023,421.76. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, VP Padmanabh P. Bhatt sold 20,000 shares of the firm’s stock in a transaction on Wednesday, January 17th. The stock was sold at an average price of $44.98, for a total value of $899,600.00. Following the transaction, the vice president now owns 32,500 shares in the company, valued at approximately $1,461,850. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 145,750 shares of company stock worth $6,173,173. Corporate insiders own 6.70% of the company’s stock.

A number of institutional investors have recently bought and sold shares of SUPN. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Supernus Pharmaceuticals by 278.2% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,018 shares of the specialty pharmaceutical company’s stock valued at $130,000 after purchasing an additional 2,220 shares during the last quarter. Riverhead Capital Management LLC increased its stake in shares of Supernus Pharmaceuticals by 91.4% in the 2nd quarter. Riverhead Capital Management LLC now owns 3,062 shares of the specialty pharmaceutical company’s stock valued at $132,000 after purchasing an additional 1,462 shares during the last quarter. Advisor Group Inc. increased its stake in shares of Supernus Pharmaceuticals by 13.7% in the 2nd quarter. Advisor Group Inc. now owns 3,395 shares of the specialty pharmaceutical company’s stock valued at $145,000 after purchasing an additional 410 shares during the last quarter. Victory Capital Management Inc. increased its stake in shares of Supernus Pharmaceuticals by 17.7% in the 2nd quarter. Victory Capital Management Inc. now owns 3,441 shares of the specialty pharmaceutical company’s stock valued at $148,000 after purchasing an additional 517 shares during the last quarter. Finally, Flinton Capital Management LLC increased its stake in shares of Supernus Pharmaceuticals by 88.9% in the 2nd quarter. Flinton Capital Management LLC now owns 4,760 shares of the specialty pharmaceutical company’s stock valued at $205,000 after purchasing an additional 2,240 shares during the last quarter. Hedge funds and other institutional investors own 98.26% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Zacks Investment Research Lowers Supernus Pharmaceuticals (SUPN) to Hold” was originally reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this story on another website, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this story can be read at https://stocknewstimes.com/2018/01/22/supernus-pharmaceuticals-supn-downgraded-by-zacks-investment-research.html.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Get a free copy of the Zacks research report on Supernus Pharmaceuticals (SUPN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply